Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2020

01-12-2020 | Ulcerative Colitis | Research article

Analysis of the pharmacological mechanism of Banxia Xiexin decoction in treating depression and ulcerative colitis based on a biological network module

Authors: Ying Yu, Gong Zhang, Tao Han, Hailiang Huang

Published in: BMC Complementary Medicine and Therapies | Issue 1/2020

Login to get access

Abstract

Background

The network pharmacology method was used to predict the active components of Banxia Xiexin decoction, its targets and the key signalling pathways that are activated in the treatment of depression and ulcerative colitis to explore the common mechanism.

Methods

The active components and targets of Banxia Xiexin decoction were obtained by searching the ETCM,TCMSP and TCMIP database. The disease targets of depression and ulcerative colitis were obtained by combining the following the DisGeNET, OMIM,Drugbank,CTD and PharmGKB disease databases. The drug and disease target genes were obtained from the intersection of the herbal medicine targets and the disease targets and were imported into the STRING platform for the analysis of PPI network. The network modules were constructed using Cytoscape software. An analysis of the functional annotations of GO terms and KEGG signalling pathways was performed for each network module. Then, the tissue distribution, sub-cellular distribution and protein attributes of the key targets in the pathway were analysed by the BioGPS, Genecards and DisGeNET databases.

Results

The mechanism of Banxia Xiexin Decoction in the treatment of depression and ulcerative colitis is related to drug reaction, steroid metabolism, lipid metabolism, inflammatory response, oxidative stress response, cell response to lipopolysaccharide, insulin secretion regulation, estradiol response and other biological functions, mainly through the regulation of 5-hydroxytryptamine synaptic, arachidonic acid metabolism, HIF-1 signaling pathway and NF-kappa B signaling pathway can achieve the effect of same treatment for different diseases.

Conclusions

The mechanism of Banxia Xiexin Decoction in treating different diseases involves direct or indirect correlation of multiple signal pathways, mainly involved in drug metabolism and lipid metabolism, but also through comprehensive intervention of the body’s nervous system, immune system, digestive system and other systems. The effective components of Banxia Xiexin Decoction are mainly act on eight key target proteins (such as ALB, IL6, VEGFA, TNF, PTGS2, MAPK1, STAT3, EGFR) to carry out multi-target effect mechanism, biological mechanism of treating different diseases with the same treatment, and related mechanism of overall treatment, which provide theoretical reference for further research on the material basis and mechanism of Banxiaxiexin decoction on antidepressant and prevention and treatment of ulcerative colitis.
Literature
1.
Friedrich MJ. Depression is the leading cause of disability around the world. JAMA. 2017;317(15):1517.PubMed
2.
Nabavi SM, Daglia M, Braidy N, et al. Natural products, micronutrients, and nutraceuticals for the treatment of depression: a short review. Nutr Neurosci. 2017;20(3):180–94.PubMed
3.
Muszynska B, Lojewski M, Rojowski J, et al. Natural products of relevance in the prevention and supportive treatment of depression. Psychiatr Pol. 2015;49(3):435–53.PubMed
4.
Liping Z. Clinical observation and discussion on the treatment of 64 cases of ulcerative colitis with Banxia Xiexin decoction. Electronic J Clin Med Literature. 2019;6(80):157.
5.
Liang H. Clinical observation on the treatment of ulcerative colitis with Banxia Xiexin decoction. Guangming J Chin Med. 2019;34(2):199–201.
6.
Haifeng R. Efficacy and safety of Banxia Xiexin decoction and its modified formula in the treatment of ulcerative colitis. Medical Equipment. 2019;32(14):85–6.
7.
Qingya L, Xiaohui W, Jie L, et al. Observation on the curative effect of 34 cases of depression treated by the combination of Chinese and Western Medicine. Chin J Tradit Med Sci Technol. 2009;16(5):389.
8.
Qisheng T, Miao Q. Integrated treatment of depression with traditional Chinese and Western Medicine. Chin J Integr Tradit West Med. 2009;29(3):283-88.
9.
Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut. 2005;54(10):1481–91.PubMedPubMedCentral
10.
Jianyi W. Clinical observation on the treatment of 64 cases of ulcerative colitis with Banxia Xiexin decoction. Guangming J Chin Med. 2008;23(4):403–4.
11.
Hongqiong P. Treatment of 64 cases of ulcerative colitis with Banxia Xiexin decoction. Laboratory Med Clinic. 2010;7(13):1377–8.
12.
Qiangwei P, Zhicui S, Xiaoli S, et al. Systematic evaluation of the efficacy and safety of Banxia Xiexin decoction and its modified and modified prescriptions in the treatment of ulcerative colitis. Chin J Exp Tradit Med Formulae. 2012;18(14):290–4.
13.
Xiaoli S. Effect of Banxia Xiexin decoction on T cell subsets CD4 and CD8 in rats with ulcerative colitis. Chin J Microcirculation. 2011;80(2):97–9.
14.
Guanghe L, Xiaojun L. The effect of Banxia Xiexin decoction on the content of inflammatory cytokines in rats with ulcerative colitis. Lishizhen Med Materia Medica Res. 2007;18(12):3028–9.
15.
Ying W, Xiaojun L. Effect of Banxia Xiexin Decoction on gastrointestinal hormones in rats with ulcerative colitis. Chinese Journal of Gerontology. Chin J Gerontol. 2011;31(14):2715–16.
16.
Bingyuan Y. Clinical observation on the treatment of depression by the combination of Chinese and Western Medicine. Guangming J Chin Med. 2009;24(9):1761–62.
17.
Qingya L, Xiaohui W, Jie L, et al. Observation on the clinical effect of fluoxetine combined with traditional Chinese medicine in the treatment ofdepression. Chin Arch Tradit Chin Med. 2009;27(9):1889–91.
18.
Zhiqiang L, Hongjuan CH. Experimental study on antidepressant effect of Banxia Xiexin decoction. Chin J Experimenl Pharmacol. 2013;19(4):280–2.
19.
20.
Xu HY, Zhang YQ, Liu ZM, et al. ETCM: an encyclopaedia of traditional Chinese medicine. Nucleic Acids Res. 2019;47(D1):D976–82.PubMed
21.
ZHAO J, YANG J, TIAN SS, et al. A survey of web resources and tools for the study of TCM networkpharmocology. Quantitative Biol. 2019;7(1):17–29.
22.
Ru J, Li P, Wang J, Zhou W, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. Cheminform. 2014;16(6):13.
23.
Haiyu X, Hongjun Y. Integrated pharmacology:a new model of modern research on traditional Chinese medicine. China J Chin Materia Medica. 2014;39(3):357–62.
24.
Xiaochun X, Jinhong H. Research methods and application progress of network pharmacology. J Pharm Pract. 2015;33(5):401–5.
25.
Haiyu X, Zhenming L, Yan F. Development and application of integrated pharmacology computing platform for traditional Chinese medicine. China J Chin Materia Medica. 2017;42(18):3633–8.
26.
Jia P, Qiang H, Junjun Y, et al. The mechanism of Banxia Xiexin decoction in the treatment of perimenopausal depression. Chin J Exp Tradit Med Formulae. 2020;26(3):15–20.
27.
Keqin Y. Modified Banxia Xiexin decoction in the treatment of 23 cases of post-stroke depression. J Tradit Chin Med. 2004;6:440–1.
28.
Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe. 2018;23(6):716–24.PubMed
29.
Fiorica-Howells E, Maroteaux L, Gershon MD. Serotonin and the 5-HT (2B) receptor in the development of enteric neurons. J Neurosci. 2000;20(1):294–305.PubMedPubMedCentral
30.
Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2013;20(1):14–21.PubMedPubMedCentral
31.
Campos B, Rivetti C, Tauler R, et al. Tryptophan hydroxylase (TRH) loss of function mutations in Daphnia deregulated growth, energetic, serotoninergic and arachidonic acid metabolic signalling pathways. Sci Rep. 2019;9(1):3693.PubMedPubMedCentral
32.
De Silva PS, Luben R, Shrestha SS, et al. Dietary arachidonic and oleic acid intake in ulcerative colitis etiology: a prospective cohort study using 7-day food diaries. Eur J Gastroenterol Hepatol. 2014;26(1):11–8.PubMed
33.
Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: tryptophan’s metabolites in exercise, inflammation, and mental health. Science. 2017;357(6349):1–8.
34.
Wang Q, Liu D, Song P, et al. Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation. Front Biosci. 2015;20(7):1116–43.
35.
Zelante T, Iannitti RG, Cunha C, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013;39(2):372–85.PubMed
36.
Chung KT, Gadupudi GS. Possible roles of excess tryptophan metabolites in cancer. Environ Mol Mutagen. 2011;52(2):81–104.PubMed
37.
Jin UH, Lee SO, Sridharan G, et al. Microbiome-derived tryptophan metabolites and their aryl-hydrocarbon-receptor-dependent agonist and antagonist activities. Mol Pharmacol. 2014;85(5):777–88.PubMedPubMedCentral
38.
Lee JS, Cella M, McDonald KG, et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on, and independent of notch. Nat Immunol. 2012;13(2):144–51.
39.
Mawe GM, Hoffman JM. Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013;10(8):473–386.PubMedPubMedCentral
40.
Quak J, Doornbos B, Annelieke MR, et al. Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms. Psychoneu Roendocrinol. 2014;3(45):202–13.
41.
Allison DJ, Ditor DS. The common inflammatory etiology of depression and cognitive impairment: a therapeutic target. J Neuroinflammation. 2014;11:151–64.PubMedPubMedCentral
42.
Xiaowen S, Mingmei Z, Haiyan Z. The research progress of traditional Chinese medicine in the treatment of depression through tryptophan canine urinary ammonia metabolic pathway. Acta Chin Med Pharmacol. 2017;45(5):98–102.
43.
Bertók L. Stress and nonspecific resistance. Ann N Y Acad Sci. 2010;851(1):1–2.
44.
Ling M, Yunan J, Yanqiu Y. New progress of hypoxia inducible factor. Progress Anatomical Sci. 2009;15(2):237–41.
45.
Mingxiao W, Rifang Y. Wan zhong Z. Progress in Proline Hydroxygenase inhibitors of hypoxia inducible factor. J Int Pharmaceutical Res. 2016;43(2):249–59.
46.
Pingping W, Fanping K, Xuequn C, et al. HIF-1 signaling pathway under hypoxic cell stress. J Zhejiang University (Medical Sciences). 2011;40(5):559–66.
47.
Lingyun L, Yuanyuan M, Xin L, et al. Expression of hypoxia-inducible factor-1alpha in hippocampus of rats with senile dementia. Chin J Gerontol. 2010;30(8):1104–5.
48.
Soucek T, Cumming R, Dargusch R, et al. The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide. Neuron. 2003;39(1):43–56.PubMed
49.
Bei ,Z, Haiqin W, Haixiong Z,et al. The surface of hippocampus in rats with vascular dementia induced by hypoxia-inducible factor-1 and erythropoietin DA. J Sichuan University (Medical Science Edition) 2006,37(5):730–733.
50.
Iyalomhe O, Swierczek S, Enwerem N, et al. The role of hypoxia-inducible factor 1 in mild cognitive impairment. Cell Mol Neurobiol. 2017;37(6):969–77.PubMed
51.
Cross RK, Wilson KT. Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis. 2003;9(3):179–89.PubMed
52.
Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 2003;112(5):645–757.PubMedPubMedCentral
53.
Mengshuang ZH, Yan D. Research progress of probiotics based on NF-κB signal pathway in the treatment of ulcerative colitis. Chinese J Microbiol. 2019;31(1):104–7.
54.
Caviedes A, Lafourcade C, Soto C, et al. BDNF/NF-kappaB signaling in the neurobiology of depression. Curr Pharm Des. 2017;23(21):3154–63.PubMed
Metadata
Title
Analysis of the pharmacological mechanism of Banxia Xiexin decoction in treating depression and ulcerative colitis based on a biological network module
Authors
Ying Yu
Gong Zhang
Tao Han
Hailiang Huang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2020
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-020-02988-3

Other articles of this Issue 1/2020

BMC Complementary Medicine and Therapies 1/2020 Go to the issue

Research article

Efficacy and safety of myrrh in patients with incomplete abortion: a randomized, double-blind, placebo-controlled clinical study

Research article

A bioinformatics investigation into the pharmacological mechanisms of javanica oil emulsion injection in non-small cell lung cancer based on network pharmacology methodologies

Research article

Findings from a three-round Delphi study: essential topics for interprofessional training on complementary and integrative medicine

Research article

The effect of curcumin ointment on knee pain in older adults with osteoarthritis: a randomized placebo trial

Research article

Protective effect of total flavonoids from Ixeris Sonchifolia on herpes simplex virus keratitis in mice

Research article

A double-blind, randomized pilot study for comparison of Melissa officinalis L. and Lavandula angustifolia Mill. with Fluoxetine for the treatment of depression